Gilead Sciences (GILD) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $1.16.
- Gilead Sciences' Debt to Equity fell 841.05% to $1.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.16, marking a year-over-year decrease of 841.05%. This contributed to the annual value of $1.38 for FY2024, which is 2580.75% up from last year.
- As of Q3 2025, Gilead Sciences' Debt to Equity stood at $1.16, which was down 841.05% from $1.27 recorded in Q2 2025.
- Gilead Sciences' Debt to Equity's 5-year high stood at $1.59 during Q1 2021, with a 5-year trough of $1.1 in Q4 2023.
- For the 5-year period, Gilead Sciences' Debt to Equity averaged around $1.28, with its median value being $1.27 (2025).
- Within the past 5 years, the most significant YoY rise in Gilead Sciences' Debt to Equity was 4640.87% (2021), while the steepest drop was 2646.33% (2021).
- Quarter analysis of 5 years shows Gilead Sciences' Debt to Equity stood at $1.27 in 2021, then fell by 6.13% to $1.19 in 2022, then decreased by 7.67% to $1.1 in 2023, then rose by 25.81% to $1.38 in 2024, then fell by 16.21% to $1.16 in 2025.
- Its Debt to Equity was $1.16 in Q3 2025, compared to $1.27 in Q2 2025 and $1.3 in Q1 2025.